Creative Planning acquired a new stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 14,013 shares of the biopharmaceutical company’s stock, valued at approximately $176,000.
Other hedge funds also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. raised its position in Amicus Therapeutics by 33.4% in the first quarter. China Universal Asset Management Co. Ltd. now owns 3,807 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 953 shares during the period. Exchange Traded Concepts LLC acquired a new stake in Amicus Therapeutics in the second quarter valued at approximately $77,000. Point72 Middle East FZE acquired a new stake in Amicus Therapeutics in the fourth quarter valued at approximately $81,000. Belpointe Asset Management LLC grew its position in Amicus Therapeutics by 1,013.1% in the first quarter. Belpointe Asset Management LLC now owns 9,172 shares of the biopharmaceutical company’s stock valued at $102,000 after acquiring an additional 8,348 shares in the last quarter. Finally, Engineers Gate Manager LP acquired a new stake in Amicus Therapeutics in the third quarter valued at approximately $106,000.
Amicus Therapeutics Price Performance
Shares of FOLD opened at $10.80 on Thursday. The firm has a market cap of $3.10 billion, a price-to-earnings ratio of -16.88 and a beta of 0.86. The stock has a 50 day moving average of $12.00 and a 200-day moving average of $12.22. The company has a current ratio of 2.72, a quick ratio of 2.40 and a debt-to-equity ratio of 3.53. Amicus Therapeutics, Inc. has a 52 week low of $9.10 and a 52 week high of $14.10.
Insider Activity
In other news, Chairman John F. Crowley sold 6,044 shares of Amicus Therapeutics stock in a transaction dated Monday, October 16th. The shares were sold at an average price of $10.50, for a total value of $63,462.00. Following the completion of the transaction, the chairman now directly owns 901,921 shares of the company’s stock, valued at approximately $9,470,170.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, CEO Bradley L. Campbell sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 1st. The stock was sold at an average price of $13.39, for a total value of $267,800.00. Following the sale, the chief executive officer now owns 798,554 shares of the company’s stock, valued at approximately $10,692,638.06. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Chairman John F. Crowley sold 6,044 shares of the firm’s stock in a transaction that occurred on Monday, October 16th. The stock was sold at an average price of $10.50, for a total value of $63,462.00. Following the completion of the sale, the chairman now directly owns 901,921 shares in the company, valued at approximately $9,470,170.50. The disclosure for this sale can be found here. In the last three months, insiders sold 122,966 shares of company stock valued at $1,599,353. Company insiders own 2.10% of the company’s stock.
Analysts Set New Price Targets
A number of research firms have weighed in on FOLD. JPMorgan Chase & Co. upped their price objective on shares of Amicus Therapeutics from $17.00 to $19.00 and gave the company an “overweight” rating in a research report on Friday, September 29th. Morgan Stanley decreased their price objective on shares of Amicus Therapeutics from $15.00 to $14.00 and set an “equal weight” rating for the company in a research report on Tuesday, October 10th. StockNews.com began coverage on shares of Amicus Therapeutics in a research report on Thursday, October 5th. They issued a “hold” rating for the company. Finally, Bank of America lifted their price target on shares of Amicus Therapeutics from $16.00 to $19.00 in a research note on Friday, September 29th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $16.00.
Get Our Latest Stock Analysis on FOLD
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data.
Read More
- Five stocks we like better than Amicus Therapeutics
- What Are Dividend Contenders? Investing in Dividend Contenders
- The top 3 stocks insiders are selling, but you shouldn’t
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Spirit AeroSystems Goes Airborne After Inking a Boeing Deal
- Basic Materials Stocks Investing
- Simon Property Group’s 7.2% Dividend Has Insiders Buying In Bulk
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
